Siyuan Xu Ph.D.

Siyuan Xu Ph.D. has worked in a variety of roles since 2012. Siyuan began as a Research Assistant at Fudan University, then moved to Dalton Venture as an Investment Professional in 2017. In 2019, they became a BD Manager at InxMed 应世物, then a Senior BD Manager at 维智药业 in 2020. In 2021, they became the Director of Business Development at ABio-X, and they currently hold the same role at RVAC Medicines since 2022.

Siyuan Xu Ph.D. began their educational journey in 2008 at Fudan University, where they obtained a Bachelor's degree in Life Science in 2012. In 2017, they completed their Doctor of Philosophy (PhD) in Biochemistry and Molecular Biology at the same university. In 2020, they received a Certificate from Tufts University School of Medicine for a Postgraduate Course in Clinical Pharmacology, Drug Development and Regulation. In 2022, they obtained a Professional Certificate Program from the Massachusetts Institute of Technology in Machine Learning, Modeling, and Simulation: Engineering Problem-Solving in the Age of AI. Prior to this, they attended High School Affiliated to Fudan University, where they obtained a Chinese high school diploma.